The United States Patent and Trademark Office (USPTO) has received an intent-to-use trademark application (TM99421485) for the mark "SYNTASE." The application, filed on September 30, 2025, covers services related to gene editing technology, specifically in vivo gene editing therapy for medical and scientific research, and pharmaceutical research and development. This filing signifies the applicant's intention to use the mark in commerce for these specified services.

This is a trademark application, not a regulatory rule or enforcement action. Compliance officers should note that this filing pertains to intellectual property protection for gene editing technologies. While it does not impose new regulatory obligations, it highlights the growing commercial interest and development in the gene editing space, which may be relevant for companies operating in the pharmaceutical and biotechnology sectors. No immediate action is required from compliance teams based solely on this trademark filing.